Natco Pharma Ltd Stock Price Today (NSE: NATCOPHARM)
Fundamental Score
Natco Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Natco Pharma Ltd share price today is ₹974.20, up +0.51% on NSE/BSE as of 30 March 2026. Natco Pharma Ltd (NATCOPHARM) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹16.16K (Cr). The 52-week high for NATCOPHARM share price is ₹1059.00 and the 52-week low is ₹726.80. At a P/E ratio of 10.50x, NATCOPHARM is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 28.00% and a debt-to-equity ratio of 0.03.
Natco Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Natco Pharma Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Natco Pharma Share Price: A Financial Analysis for Industry Dominance
The pharmaceutical industry is currently experiencing a shift towards specialty generics and complex APIs, offering companies with strong R&D capabilities a significant advantage. This analysis examines the financial health of Natco Pharma Ltd, focusing on its potential for long-term growth and industry dominance. This analysis begins with reviewing the Natco Pharma share price, currently at ₹823.549988. The price-to-earnings (PE) ratio is 10.5, and the Return on Capital Employed (ROCE) stands at an impressive 32.78%.
The relatively low PE ratio of 10.5 may suggest that Natco Pharma is undervalued compared to its earnings, especially considering the sector's growth prospects. A deeper dive into the company's financials would be necessary to confirm this hypothesis, examining factors such as debt levels and future earnings projections. In contrast, observing
Mankind Pharma Ltd, one might investigate their management quality through metrics like employee retention rates and leadership stability compared to Natco's leadership team, potentially offering insights into each company’s strategic direction and execution capabilities.The standout metric is the ROCE of 32.78%. A high ROCE indicates that Natco Pharma is efficiently generating profits from its capital investments. This strong return contributes significantly to the company's competitive advantage or "moat." A higher ROCE than its peers suggests a greater ability to reinvest profits, fund research and development, and potentially acquire other businesses, ultimately strengthening its position in the market.
While financial metrics paint a picture of current performance, understanding the sustainability of this performance is key. Examining Natco Pharma's pipeline of new products, its regulatory approvals record, and its ability to maintain pricing power will offer a more comprehensive perspective on its long-term prospects. A detailed review of the cash flows, especially free cash flow, is also recommended.
Disclaimer: This financial analysis is part of a larger, 80-parameter fundamental audit verified by Sweta Mishra. This is an observational analysis and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Natco Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NATCOPHARM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (28.00%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (32.78%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (38.03%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 10.50 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (18.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (33.70% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (33.27% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (61.04x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹2778.40 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Profit Decline Concern (-23.46%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Natco Pharma Ltd Financial Statements
Comprehensive financial data for Natco Pharma Ltd including income statement, balance sheet and cash flow
About NATCOPHARM (Natco Pharma Ltd)
Natco Pharma Ltd is a vertically integrated pharmaceutical powerhouse, carving a niche for itself in the complex world of oncology and specialty medicines. They are not merely manu...facturers; they are innovators, meticulously crafting finished dosage formulations and active pharmaceutical ingredients (APIs) with a focus on cutting-edge research and development. Their commitment extends beyond national borders, establishing a significant presence in both domestic and international markets. This dedication to research, coupled with strategic manufacturing capabilities, allows Natco Pharma to address unmet medical needs with accessible and high-quality pharmaceuticals, particularly in areas where treatment options are limited or prohibitively expensive. They stand as a testament to the power of scientific rigor and ethical business practices within the pharmaceutical landscape. The company's strategic vision encompasses a diverse therapeutic portfolio, reflecting a deep understanding of global healthcare needs. While oncology remains a cornerstone of their operations, Natco Pharma is also actively involved in developing solutions for other critical disease areas. This includes, but is not limited to, treatments for cardiovascular ailments, neurological disorders, and various autoimmune conditions. The breadth of their product pipeline underscores their commitment to addressing a wide range of patient needs, from chronic conditions to life-threatening illnesses. This multifaceted approach enables Natco Pharma to contribute meaningfully to improving patient outcomes worldwide. Beyond their immediate product offerings, Natco Pharma embodies a forward-thinking approach to healthcare. They are actively investing in the development of novel drug delivery systems and exploring biosimilar opportunities to expand access to affordable, life-saving medications. Their dedication to innovation extends beyond the laboratory, encompassing a commitment to ethical sourcing and responsible manufacturing practices. This holistic approach, combined with a strong focus on patient well-being, positions Natco Pharma as a responsible and impactful contributor to the global pharmaceutical industry, poised to shape the future of healthcare.
Company Details
Key Leadership
Corporate Events
Latest News
NATCOPHARM Share Price: Frequently Asked Questions
What is the current share price of Natco Pharma Ltd (NATCOPHARM)?
As of 30 Mar 2026, 12:06 pm IST, Natco Pharma Ltd share price is ₹974.20. The NATCOPHARM stock has a market capitalisation of ₹16.16K (Cr) on NSE/BSE.
Is NATCOPHARM share price Overvalued or Undervalued?
NATCOPHARM share price is currently trading at a P/E ratio of 10.50x, compared to the industry average of 31.77x. Based on this relative valuation, the Natco Pharma Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of NATCOPHARM share price?
The 52-week high of NATCOPHARM share price is ₹1059.00 and the 52-week low is ₹726.80. These values are updated daily from NSE/BSE price data.
What factors affect the Natco Pharma Ltd share price?
Key factors influencing NATCOPHARM share price include quarterly earnings growth (Sales Growth: -0.59%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Natco Pharma Ltd a good stock for long-term investment?
Natco Pharma Ltd shows a 5-year Profit Growth of 33.27% and an ROE of 28.00%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing in NATCOPHARM shares.
How does Natco Pharma Ltd compare with its industry peers?
Natco Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare NATCOPHARM share price P/E of 10.50x and ROE of 28.00% against the industry averages to determine competitive standing.
What is the P/E ratio of NATCOPHARM and what does it mean?
NATCOPHARM share price has a P/E ratio of 10.50x compared to the industry average of 31.77x. Investors pay ₹11 for every ₹1 of annual earnings.
How is NATCOPHARM performing according to Bull Run's analysis?
NATCOPHARM has a Bull Run fundamental score of 60.3/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does NATCOPHARM belong to?
NATCOPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Natco Pharma Ltd share price.
What is Return on Equity (ROE) and why is it important for NATCOPHARM?
NATCOPHARM has an ROE of 28.00%, which indicates excellent management efficiency. ROE measures how efficiently Natco Pharma Ltd generates profits from shareholders capital.
How is NATCOPHARM debt-to-equity ratio and what does it indicate?
NATCOPHARM has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk.
What is NATCOPHARM dividend yield and is it a good dividend stock?
NATCOPHARM offers a dividend yield of 0.66%, meaning you receive ₹0.66 annual dividend for every ₹100 invested in Natco Pharma Ltd shares.
How has NATCOPHARM share price grown over the past 5 years?
NATCOPHARM has achieved 5-year growth rates of: Sales Growth 18.26%, Profit Growth 33.27%, and EPS Growth 33.70%.
What is the promoter holding in NATCOPHARM and why does it matter?
Promoters hold 49.48% of NATCOPHARM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Natco Pharma Ltd.
What is NATCOPHARM market capitalisation category?
NATCOPHARM has a market capitalisation of ₹16158 crores, placing it in the Mid-cap category.
How volatile is NATCOPHARM stock?
NATCOPHARM has a beta of N/A. A beta > 1 suggests the Natco Pharma Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is NATCOPHARM operating profit margin trend?
NATCOPHARM has a 5-year average Operating Profit Margin (OPM) of 38.03%, indicating the company's operational efficiency.
How is NATCOPHARM quarterly performance?
Recent quarterly performance shows Natco Pharma Ltd YoY Sales Growth of -0.59% and YoY Profit Growth of -23.46%.
What is the institutional holding pattern in NATCOPHARM?
NATCOPHARM has FII holding of 14.09% and DII holding of 5.87%. Significant institutional holding often suggests professional confidence in the Natco Pharma Ltd stock.